title: Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro.
abstract: Apoptosis can be regulated in a number of different systems by the actions of cytokines. Rapamycin has been shown to exert its effects on growth factor-induced cell proliferation, at least in part, by blocking the activation of the p70 S6 kinase and thus preventing the downstream signaling process, such as the activation of the members of the cdk family. To determine whether this pathway plays a role in the regulation of apoptosis, we assessed the effect of rapamycin on apoptosis induced by interleukin 2 deprivation in murine T-cell lines, by T-cell receptor ligation in a murine T-cell hybridoma, by enforced c-myc expression in murine fibroblasts, and by corticosteroids in murine T-lymphoma cell lines. Although rapamycin did not induce apoptosis on its own, rapamycin augmented apoptosis in each of the cell lines used as indicated by increased genomic DNA fragmentation, decreased cell viability, and characteristic apoptotic changes in morphology. These results suggest that a signal transduction pathway(s) inhibited by rapamycin plays an important role in the susceptibility of cells to apoptosis. Many chemotherapeutic agents kill cancer cells through the induction of apoptosis. Strikingly, rapamycin increased the ability of the alkylating agent, cisplatin, to induce apoptosis in the human promyelocytic leukemia cell line HL-60 and the human ovarian cancer cell line SKOV3. These data suggest that a signal transduction pathway, likely related to p70 S6 kinase, inhibited by rapamycin may be an important component of the pathway which prevents cell death in many cell lineages and also indicate that rapamycin has the potential to augment the efficacy of selected anticancer therapies.
authors.affiliation: Toronto Hospital, Canada.
authors.forename: Y
authors.initials: Y
authors.lastname: Shi
authors.forename: A
authors.initials: A
authors.lastname: Frankel
authors.forename: L G
authors.initials: LG
authors.lastname: Radvanyi
authors.forename: L Z
authors.initials: LZ
authors.lastname: Penn
authors.forename: R G
authors.initials: RG
authors.lastname: Miller
authors.forename: G B
authors.initials: GB
authors.lastname: Mills
mesh_terms: D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D002945:Cisplatin / Q000008:administration & dosage; D006224:Cricetinae; D004357:Drug Synergism; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy / Q000473:pathology; D008213:Lymphocyte Activation; D051379:Mice; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000473:pathology; D011090:Polyenes / Q000008:administration & dosage / Q000494:pharmacology*; D012680:Sensitivity and Specificity; D020123:Sirolimus; D013601:T-Lymphocytes / Q000166:cytology / Q000187:drug effects; D014407:Tumor Cells, Cultured / Q000187:drug effects
chemical_list: D007166:Immunosuppressive Agents; D011090:Polyenes; D002945:Cisplatin; D020123:Sirolimus